Bristol Myers Squibb is adding to its protein degrader lineup, which already includes the likes of A-Alpha Bio and Evotec, by linking arms with a little-known biotech that’s been communicating with the scientists at Celgene for the past few years.
The Big Pharma is investing in SyntheX and laying out…
